News
Company News
Astrocyte Pharmaceuticals Completes $2.4M Seed Financing Round
Cambridge, MA, July 17, 2017 – Astrocyte Pharmaceuticals Inc. announced today that it has completed its seed financing round raising over $2.4M. The company is developing novel small molecule drugs that limit neuronal damage in patients that have suffered a stroke, traumatic brain injury (TBI) or concussion. As previously announced, the seed financing round was […]
Astrocyte Pharmaceuticals Raises Over $1.3M in Seed Financing Round
Cambridge, MA, March 24, 2017 – Astrocyte Pharmaceuticals Inc., a CNS therapeutics startup, announced today that it has raised approximately $1.36M in a seed financing round. The company is developing novel small molecule drugs that limit neuronal damage in patients that have suffered a stroke, traumatic brain injury (TBI) or concussion. The seed financing round […]
Former Army TBI Research Leader Col. Dallas Hack Joins Astrocyte Pharmaceuticals’ Scientific Advisory Board
Cambridge, MA, December 19, 2016 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, announced today that Colonel (retired) Dallas C. Hack, MD, MPH has joined the company’s Scientific Advisory Board. Astrocyte Pharmaceuticals is developing novel small molecule therapeutics for acute administration to patients who have suffered a stroke, traumatic brain injury (TBI) or concussion. […]
In the Media
“To Curb Brain Damage, Astrocyte Pharmaceuticals Energizes Cells” article in Xconomy by David Holley.
Company Profile published by Nature Biopharma Dealmakers in the September 2015 issue dedicated to Neuroscience companies and their research.
- The full issue can be viewed here.
- The Astrocyte Pharmaceuticals profile page is here: Nature Biopharma Dealmakers – Astrocyte Pharmaceuticals Profile. Sept. 2015.
“Pursuing Concussion’s Cure” article in the Mission magazine by Will Samsom
Coverage by International Innovation in the May 20th 2014 issue (Issue 142), “A Brainy Bunch” (free registration required)